JNJ vs KRYS

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Krystal Biotech maintains its strong '10x potential' trajectory. Vyjuvek's continued robust commercial performance for DEB provides a solid financial base, validating execution. The proprietary STAR-D platform, particularly the AATD program, shows accelerated progress with pivotal clinical readouts anticipated to significantly expand the Total Addressable Market. The leadership's proven ability to...